Evidence map›Paper›PMID 33173865›Full record

ArticlebioRxiv : the preprint server for biology2020

Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.

Rory D de Vries, Katharina S Schmitz, Francesca T Bovier, Danny Noack, Bart L Haagmans, Sudipta Biswas, Barry Rockx, Samuel H Gellman, Christopher A Alabi, Rik L de Swart and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 30 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Rory D de VriesDepartment Viroscience, Erasmus MC, Rotterdam, the Netherlands.
Katharina S SchmitzDepartment Viroscience, Erasmus MC, Rotterdam, the Netherlands.
Francesca T BovierDepartment of Pediatrics, Columbia University Medical Center, New York, NY, USA.
Danny NoackDepartment Viroscience, Erasmus MC, Rotterdam, the Netherlands.
Bart L HaagmansDepartment Viroscience, Erasmus MC, Rotterdam, the Netherlands.
Sudipta BiswasRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
Barry RockxDepartment Viroscience, Erasmus MC, Rotterdam, the Netherlands.
Samuel H GellmanDepartment of Chemistry, University of Wisconsin, Madison, WI, USA.
Christopher A AlabiRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
Rik L de SwartDepartment Viroscience, Erasmus MC, Rotterdam, the Netherlands.
Anne MosconaDepartment of Pediatrics, Columbia University Medical Center, New York, NY, USA.
Matteo PorottoDepartment of Pediatrics, Columbia University Medical Center, New York, NY, USA.
Erasmus MC · NLCornell University · USUniversity of Campania "Luigi Vanvitelli" · ITColumbia University Irving Medical Center · USUniversity of Wisconsin–Madison · US

Funding

Engineering protease-resistant alpha-beta peptides for broad-spectrum antiviralsR01AI114736 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2015 to 2019
$3.7M
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agentsR01AI121349 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2016 to 2020
$3.2M
Mechanisms of measles virus CNS adaptationR01NS091263 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2015 to 2019
$1.9M
Small molecules to block measles spreading in the central nervous systemR56AI146980 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2019 to 2019
$493k
NIAID NIH HHS R01 AI114736NIAID NIH HHS R01 AI121349NIAID NIH HHS R56 AI146980NINDS NIH HHS R01 NS091263
6 · The paper itself

Abstract

Containment of the COVID-19 pandemic requires reducing viral transmission. SARS-CoV-2 infection is initiated by membrane fusion between the viral and host cell membranes, mediated by the viral spike protein. We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets. Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co-housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals. These lipopeptides are highly stable and non-toxic and thus readily translate into a safe and effective intranasal prophylactic approach to reduce transmission of SARS-CoV-2. ONE-SENTENCE SUMMARY: A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection

Identifiers

PMID33173865
PMCPMC7654853
OpenAlexW3096534747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.